Thursday , December 13 2018
Breaking News
Home / BUSINESS / Lupin launches generic Atovaquone Oral Suspension USP in US
Lupin launches generic Atovaquone Oral Suspension USP in US

Lupin launches generic Atovaquone Oral Suspension USP in US

Lupin has launched Atovaquone Oral Suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration (USFDA) earlier.

Lupin’s Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC’s Mepron oral suspension 750 mg/5 ml. It is indicated for the prevention of Pneumocystis jirovecii pneuomonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprimsulfamethoxazole (TMP-SMX). It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX.

Atovaquone Oral Suspension USP, 750 mg/5 mL had annual sales of approximately $119 million in the US (IQVIA MAT September 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Leave a Reply

Your email address will not be published. Required fields are marked *

*